If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Trulicity Summary of Product Characteristics (SmPC)
Trulicity® (dulaglutide): Switching From Another GLP-1 Receptor Agonist
No studies have been done on the effects of switching from another GLP-1 RA to dulaglutide.
is a GLP-1 RA indicated for once weekly dosing as an adjunct to diet
and exercise for the treatment of adults with unsufficiently
studies have been performed regarding switching to dulaglutide from
another GLP-1 RA.
should follow their clinical judgment, taking into account the
patient’s glycemic control, when deciding how to switch from
one GLP-1 RA to another one.
switching a patient from another GLP-1 RA to dulaglutide, the
prescribing information of the applicable GLP-1 RA and
pharmacokinetic profile should be considered including
to steady state, and
in glycemic control with dulaglutide after the first administration
is sustained throughout the once weekly dosing interval. The
half-life of dulaglutide is approximately 5 days and steady-state
concentrations of dulaglutide are achieved within 2 to 4 weeks.1
Trulicity [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
= type 2 diabetes mellitus
RA = glucagon-like peptide-1 receptor agonist
Date of Last Review:October 11, 2018
Was this answer helpful to you?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at email@example.com